Celldex Therapeutics

CLDX Lead: Phase 3 4 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-15

Catalyst timeline

Barzolvolimab commercial manufacturing update2026Barzolvolimab commercial manufacturing update, 2026, routine
Barzolvolimab Prurigo Nodularis Ph2 toplineSummer 2026Barzolvolimab Prurigo Nodularis Ph2 topline, Summer 2026, major
CDX-622 Ph1 readout3Q 2026CDX-622 Ph1 readout, 3Q 2026, notable
Barzolvolimab CSU Ph3 toplineOct 2026Barzolvolimab CSU Ph3 topline, Oct 2026, thesis-defining
Barzolvolimab Atopic Dermatitis Ph2 toplineOct 2026Barzolvolimab Atopic Dermatitis Ph2 topline, Oct 2026, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

barzolvolimab

CDX-0159

Protein Target: KIT

Chronic Spontaneous Urticaria Phase 3 subcutaneous NCT04538794
Symptomatic Dermographism Phase 3 subcutaneous NCT04548869
Atopic Dermatitis Phase 2 subcutaneous NCT06727552
Chronic Inducible Urticaria Phase 3 subcutaneous NCT05405660

CDX-622

Protein Target: TSLP, SCF

Asthma Phase 1 intravenous NCT07330778
Allergic Rhinitis
Food Allergy

Technology platforms

Bispecific Antibody Platform

Next generation bispecific antibody platform supporting pipeline expansion with additional candidates for inflammatory diseases. Targets selected based on new science and compatibility with existing antibody programs in bispecific formats. Focus on emerging pathways controlling inflammatory diseases.

Discontinued (2)

barzolvolimab — Prurigo Nodularis · missed primary and key secondary endpoints in Phase 2
barzolvolimab — Eosinophilic Esophagitis · mast cell depletion did not result in improvement in EoE symptoms or endoscopic assessment compared to placebo

Biotech Distilled coverage (4)

2026-08-07 UPDATE: Celldex Therapeutics (CLDX) - Countdown to the Coin Flip 🔒 Paid
2026-07-21 UPDATE: Celldex Therapeutics (CLDX) - The PN Program Just Got Killed 🔒 Paid
2026-06-15 UPDATE: Celldex Therapeutics (CLDX) - The Bear Case Just Lost a Tooth
2026-04-16 Celldex Therapeutics (CLDX) - Scientific Deep Dive for Barzolvolimab and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.